FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

• by Kathryn Wighton

• June 2, 2026

Extended antiviral therapy may not improve long COVID

Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.

• by Andrea Surnit

• September 4, 2026

• 4 min

High-Efficiency Particulate Air Filters to Prevent Winter Respiratory Infections in Care Homes: The AFRI-c

• by Alastair D. Hay, Rachel C. M. Brierley, Nick Turner, Joanna C. Thorn, Sophie Rees, Claire E. Brown, Laurel Campbell-Smith, Eleanor A. Gidman, Emily J. Henderson, Graziella Mazza, Gemma Morgan, Derren Ready, Craig Riddington, Jane Sprackman, Jodi Taylor, Tomas Welsh, Ruth Kipping

• September 1, 2026

Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022–2023 and 2023–2024 seasons

• by Mahrukh Imran, Benjamin Chastek, Tim Bancroft, Noah Webb, Stephen I. Pelton, Mendel D.M. Haag, Ian McGovern

• September 1, 2026